Table 1.
Frequencies of XRCC3 Thre241Met, RAD51 G135Cand GSTM1 null polymorphisms in AML and control populations and the relative risk of AML associated with those genotypes
| Genotype | Controls | AML | OR (95% CI) | P-value | |
|---|---|---|---|---|---|
| n | n | ||||
| XRCC3 Thr241Met | 646 | 413 | |||
| Thr/The | 253 | 168 | 1.0 (Ref) | ||
| Thr/Met | 309 | 190 | 0.93 (0.71–1.21) | 0.571 | |
| Met/Met | 84 | 55 | 0.99 | 0.944 | |
| Thr/Met+Met/Met | 393 | 245 | 0.94 | 0.623 | |
| RAD51 G135C | 646 | 452 | |||
| G/G | 555 | 374 | 1.0 (Ref) | ||
| G/C | 85 | 73 | 1.27 (0.91–1.79) | 0.161 | |
| C/C | 6 | 5 | 1.24 (0.37–4.08) | 0.727 | |
| G/C+C/C | 91 | 78 | 1.27 (0.91–1.77) | 0.153 | |
| GSTM1 | |||||
| Mu+ | 340 | 243 | 1.0 (Ref) | ||
| Mu− | 299 | 218 | 1.07 (0.84–1.36) | 0.591 | |
Abbreviations: AML, acute myeloid leukemia; CI, confidence intervals.